Patent ID: 9746481
Date: 2017-08-29
CPC Classifications: C07K,G01N

Claim:
1. A method of detecting brain injury in a patient, the method comprising the steps of: a. contacting a biological sample from the patient with an antibody that specifically binds biomarker glial fibrillary acidic protein (GFAP), an antibody that specifically binds biomarker neurogranin (NRGN) and an antibody that specifically binds one of Astrotactin 1 (ASTN1), Brain Angiogenesis Inhibitor 3 (BAI3), Carnosine Dipeptidase 1 (CNDP1), Ermin (ERMN), Glutamate Receptor Metabotropic 3 (GRM3), Ketch-Like Protein 32 (KLH32), Melanoma Antigen Family E2 (MAGE2), Neuregulin 3 (NRG3), Oligodendrocyte Myelin Glycoprotein (OMG), Solute Carrier Family 39 (zinc transporter) member 12 (SLC39A12), and reticulon 1 (RTN1) in the sample; and b. detecting binding of the antibodies to the biomarkers, wherein detection of an increase in the levels of said biomarkers relative to an appropriate control detects brain injury in the patient.